FDA Launches One-Day Inspectional Assessment Pilot Across Multiple Inspectorates in April 2026

A compressed inspection format is now active across FDA programs, and plant heads should treat the agency's new one-day assessments as a live signal of how risk-based oversight is being operationalised. The FDA confirmed on 6 May 2026 that a pilot of one-day inspectional assessments launched in April, running concurrently with standard inspections rather than replacing them.

Approximately 46 assessments had been completed as of late April, spanning human and animal foods, biologics, medical products, and clinical research programs. The agency reported that most resulted in No Action Indicated (NAI) outcomes, though the pilot has already demonstrated scope flexibility: assessments extended beyond one day where significant observations were identified, and investigators retain full authority to escalate duration or coverage at their discretion.

Facility selection is driven by risk-based criteria including product type, prior inspection history, and operational characteristics. For QA directors, the compliance read is direct: data gathered during these assessments, including recurring compliance themes, facility-specific risk scores, and discrepancies between registered and actual operations, will feed into the agency's broader risk models and inform targeting of future standard inspections. A facility that draws an expanded assessment now may find itself prioritised for a full inspection later in the cycle.

FDA Associate Commissioner for Inspections and Investigations Elizabeth Miller, Pharm.D., stated the agency is analysing outcome trends, risk signals, and investigator feedback to determine how the format integrates into the wider inspectional strategy. FDA Commissioner Marty Makary, M.D., M.P.H., framed the format as enabling broader surveillance coverage with reduced operational disruption, particularly for lower-risk establishments, without compromising regulatory rigor.

The pilot does not apply to higher-risk or complex facilities requiring comprehensive inspectional coverage, and the agency has confirmed it does not represent a change in enforcement policy. Evaluation metrics under development include inspection duration, escalation rates, and the utility of findings in risk-based decision-making. The pilot is scheduled to continue through fiscal year 2026, with additional assessments planned across all participating inspectorates.

The measurable outcome to watch is escalation rate: as that figure is formalised into FDA's evaluation framework, it will become a direct indicator of how the one-day format is reshaping the agency's risk-tiering of the facility population.

Source: FDA Press Releases RSS Feed via fda.gov, 6 May 2026.